The authors of the manuscript would like to correct affiliation of Mr. Nobuo Shirahashi, who was mentioned in the Appendix section of this article. The correct affiliation of Mr. Shirahashi was Novartis Pharma KK and Department of Preventive Medicine and Environmental Health, Osaka City University Medical School, Osaka, Japan.
Article info
Publication history
Published online: January 30, 2015
Identification
Copyright
© 2015 Japanese College of Cardiology. Published by Elsevier Inc.
User license
Elsevier user license | How you can reuse 
Elsevier's open access license policy
Elsevier user license
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy
ScienceDirect
Access this article on ScienceDirectLinked Article
- Rationale and design of the NAGOYA HEART Study: Comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intoleranceJournal of CardiologyVol. 56Issue 1
- PreviewInhibitors of the renin angiotensin system are recommended as the first-line medications for diabetic hypertensive patients. However, there is less evidence supporting this recommendation especially among East Asians, a population with a unique distribution of cardiovascular disease compared to the Western population.
- Full-Text
- Preview
